- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Clinical trials of medicines, vaccines often carried out in poor countries: SC
New Delhi: Observing that clinical trials of medicines and vaccines are often conducted in poor countries, the Supreme Court has permitted a petitioner to submit objections to the rules established by the Centre on the matter.
A bench comprising Justices Hrishikesh Roy and S. V. N. Bhatti noted, “We know that the clinical trials are conducted in poor countries."
The bench considered submissions made by the Centre's Additional Solicitor General, Archana Pathak Dave, who noted that rules for new drugs and clinical trials had been framed in 2019.
Following the rules, Dave said New Drugs and Clinical Trials (Amendment) Rules were notified in 2024 to streamline the approval process for clinical trials and new drugs in India which aimed to improve patient safety protocols and ensure compliance with global standards.
This follows a public interest litigation (PIL) filed by an NGO Swasthya Adhikar Manch in 2012 alleging large-scale clinical drug trials across the country by multinational pharmaceutical firms, PTI reported.
Senior advocate Sanjay Parikh, appearing for NGO, said poor citizens were still being used as "guinea pigs" and not paid adequate compensation.
The senior lawyer said he wanted to file his objections and submissions in the case to ensure a proper redressal of the grievances.
Dave, however, said the PILs had become infructuous as the rules and the amendments were notified in 2019 and 2024, respectively, and nothing remained to be dealt with.
The top court granted four weeks to Parikh to file his objections to the rules and otherwise.
Clinical trials in India are governed by several rules, including the approval of the Drugs Controller General of India for such trials.
The 2024 rules were intended to make changes to the existing ones introduced in 2019.
The top court had said clinical trials in the country must be for the help of people in the country and not be allowed for the benefits of multinational companies.
In 2013, it said norms formulated by the Centre were "deficient" to protect the rights of the subjects following which new rules were introduced.
The PIL alleged clinical drug trials by various pharmaceutical firms took place indiscriminately across states in the country and used Indian citizens as guinea pigs.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751